Lake Street Capital Issues Positive Forecast for Avita Medical (NASDAQ:RCEL) Stock Price

Posted by Geri Gentry on Nov 9th, 2026

Avita Medical (NASDAQ:RCEL – Free Report) had its price target lifted by Lake Street Capital from $12.00 to $20.00 in a report published on Friday,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Several other equities analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avita Medical in a report on Monday, September 21st. BTIG Research raised their price objective on shares of Avita Medical from $15.00 to $21.00 and gave the stock a “buy” rating in a research note on Friday. Wall Street Zen upgraded Avita Medical from a “sell” rating to a “hold” rating in a research report on Sunday, August 2nd. Finally, TD Cowen restated a “buy” rating on shares of Avita Medical in a research report on Tuesday, November 3rd. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Avita Medical has a consensus rating of “Moderate Buy” and an average price target of $15.00.

View Our Latest Report on Avita Medical

Avita Medical Price Performance

NASDAQ RCEL opened at $16.59 on Friday. Avita Medical has a 52 week low of $3.22 and a 52 week high of $18.07. The firm has a market capitalization of $521.26 million, a price-to-earnings ratio of -14.06 and a beta of 2.03. The company has a fifty day moving average of $12.77 and a two-hundred day moving average of $6.85.

Avita Medical (NASDAQ:RCEL – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. The firm had revenue of $26.11 million during the quarter, compared to analysts’ expectations of $22.35 million. Equities research analysts anticipate that Avita Medical will post -0.98 EPS for the current year.

Hedge Funds Weigh In On Avita Medical

Hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its stake in Avita Medical by 28.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock worth $191,000 after purchasing an additional 3,500 shares in the last quarter. Harpswell Capital Advisors LLC purchased a new position in Avita Medical during the 3rd quarter worth $150,000. Russell Investments Group Ltd. increased its holdings in Avita Medical by 47.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 41,449 shares of the company’s stock worth $486,000 after purchasing an additional 13,395 shares during the period. Quantinno Capital Management LP bought a new stake in Avita Medical during the 1st quarter valued at $83,000. Finally, Squarepoint Ops LLC bought a new stake in Avita Medical during the 2nd quarter valued at $95,000. 27.66% of the stock is currently owned by institutional investors.

About Avita Medical

(Get Free Report)

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on developing and commercializing therapies that use a patient’s own cells to help restore damaged skin and tissue. Its lead product is the RECELL System, an autologous cell-harvesting device designed to prepare a suspension of a patient’s skin cells at the point of care for application to wounds.

RECELL is used in the treatment of certain thermal burn wounds and other skin injuries. The system is intended to support wound healing and may reduce the amount of donor skin required for grafting by enabling clinicians to create a cell suspension from a small sample of the patient’s healthy skin.